Physician

Jeffrey R Uzzilia, MD

According to 2025 Medicare claims, Jeffrey Uzzilia, MD (NPI: 1548444664) practices cardiology in the Albany-Schenectady-Troy, NY market, with the plurality of this provider's patient population coming from Albany, NY. This provider's primary affiliated billing organization is CAPITAL CARDIOLOGY ASSOCIATES PLLC (NPI: 1518952332; TIN: 141834454) and primary practice location at 12211-2526.

Uzzilia's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,992 traditional Medicare patients, billed 24,225 HCPCS/CPT codes, and received $817,532 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 16,426 prescription claims across 1,982 beneficiaries totaling $3,373,981 in drug costs, led by Eliquis (Apixaban). 2019 DME data shows 30 claims. Open Payments data shows 47 records totaling $710. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $425,365 to $817,532. Similarly, Part D prescription costs have moved sharply higher in recent years, from $443,541 to $3,373,981. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,280	14,755	$425,365
2016	2,309	15,567	$474,692
2017	2,281	18,255	$593,882
2018	1,907	16,809	$678,204
2019	1,907	18,522	$637,424
2020	1,711	16,290	$572,374
2021	1,961	16,268	$664,885
2022	1,878	16,695	$689,428
2023	1,916	21,647	$726,378
2024	1,992	24,225	$817,532

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	645	4,699	$443,541
2016	842	6,163	$641,254
2017	1,005	7,816	$888,758
2018	1,148	9,170	$1,123,895
2019	1,290	10,035	$1,366,324
2020	1,486	12,203	$1,892,314
2021	1,675	14,045	$2,576,391
2022	1,802	15,714	$3,426,825
2023	1,918	17,124	$3,534,807
2024	1,982	16,426	$3,373,981

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	24	$830
2018	N/R	N/R	N/R
2019	N/R	30	$5,008
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	1,016	1,302	$84
99426	Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month	320	1,109	$47
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	1,032	1,342	$11
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	1,053	1,347	$10
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	347	453	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	980	73,960	$1,386,253
Vyndamax	Tafamidis	25	870	$584,807
Entresto	Sacubitril/Valsartan	216	15,468	$312,600
Xarelto	Rivaroxaban	114	9,200	$169,132
Repatha Sureclick	Evolocumab	129	7,744	$149,753

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	47	$710	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeffrey R. Uzzilia, MD?

Tedicare shows public-source Medicare data for Jeffrey R. Uzzilia, MD (NPI 1548444664), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeffrey R. Uzzilia, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jeffrey R. Uzzilia, MD?

Jeffrey R. Uzzilia, MD is linked to CAPITAL CARDIOLOGY ASSOCIATES PLLC (billing NPI 1518952332) in the available physician profile data.

Does Jeffrey R. Uzzilia, MD have Open Payments data?

Jeffrey R. Uzzilia, MD has 47 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.